Follow on Google News News By Tag Industry News News By Location Country(s) Industry News
Follow on Google News | HPAPI 2019 Conference: Exclusive Interview Released with AstraZenecaPeter Marshall from AstraZeneca interview ahead of the Highly Potential Active Pharmaceutical Ingredients Conference
By: SMi Group Ltd Peter said: "The HPAPI market is becoming more entrenched across the Pharma industry. Historically major pharma and some specialist contract manufacturers have led the field in design and application, but the more general toxic nature of new products has required many more companies to consider investment in contained facilities. Further to this, new drug modalities such as ADCs (antibody-drug conjugates) have presented enhanced containment challenges due to the elevated toxicity of some of the components. Finally, the toxicity of some modern inhaler and other device products has raised the importance of containment in device-related process approaches including dry powder and aseptic filling processes." "For me personally, the problem is often being involved in the early stages of a project to ensure that exposure control is properly considered, and optimal strategies and technologies are applied. In my opinion there are too many simplistic design or equipment selection tools which are used blindly without an understanding of their relevance and validity. In some cases these can lead to excessively conservative technology decisions which present significant operability and maintenance issues for the final user." The full interview is available in the Download Centre at https://www.smi- Key sessions to be discussed in the area of containment include – Antibody-drug conjugate manufacturing, adaptation of containment designs to cope with the high demands of HPAPIs and the challenges verifying containment performance of a HPAPI OSD facility. Joining Peter on Day Two of the conference will be Dr Thomas Nittoli, Director, Regeneron; Dr Jeff Parry, Senior Formulation Scientist, AstraZeneca and Mr Nigel Saunders, Technical Engineer – SME Containment, GSK. Sponsors include: BSP Pharmaceuticals | Minakem | PCi Pharma Services | SafeBridge Consultants Inc. | Solo Containment For media enquiries contact Neill Howard on Tel: +44 (0)20 7827 6164 / Email: nhoward@smi- End
Account Email Address Account Phone Number Disclaimer Report Abuse
|
|